TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Randomized Placebo-Controlled Trial of Bactrim on 7 Day Outcome in Emergency Department Patients With Uncomplicated Abscesses at Risk for Community Acquired Methicillin Resistant Staph Aureus
Brief Summary: Patients will be enrolled in a multi-center study to prospectively evaluate outcome after treatment for an uncomplicated skin abscess. All patients will receive incision and drainage and wound cultures. Patients will then be randomized to 1) placebo two tablets PO BID X 7 days or 2) bactrim DS (800/160) two tablets PO BID x 7 days. Patients will then return to the emergency department ED) at 48 hours and 7 for wound repacking and evaluation. The primary outcome is treatment failure rates at 7 days after incision and drainage. Patients who are clinically worsening or not improving after 48 hours will then be treated with additional antibiotics or admission if needed. Data will be analyzed both by initial randomization and intention to treat.


Options:
A: Arm Label: Ceftaroline fosamil for Injection; Type: EXPERIMENTAL; Interventions: Drug: ceftaroline, Drug: Placebo | Arm Label: IV Vancomycin plus IV Aztreonam; Type: ACTIVE_COMPARATOR; Interventions: Drug: vancomycin plus aztreonam | Intervention Type: DRUG; Name: ceftaroline; Assigned to Arm(s): Ceftaroline fosamil for Injection | Intervention Type: DRUG; Name: vancomycin plus aztreonam; Assigned to Arm(s): IV Vancomycin plus IV Aztreonam | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Ceftaroline fosamil for Injection
B: Arm Label: Moxifloxacin; Type: EXPERIMENTAL; Interventions: Drug: Moxifloxacin (Avelox, BAY12-8039) | Arm Label: PIP/TAZ-AMC; Type: ACTIVE_COMPARATOR; Interventions: Drug: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid | Intervention Type: DRUG; Name: Moxifloxacin (Avelox, BAY12-8039); Assigned to Arm(s): Moxifloxacin | Intervention Type: DRUG; Name: Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid; Assigned to Arm(s): PIP/TAZ-AMC
C: Arm Label: bactrim DS (800/160) 2 pills po BID x 7 days; Type: ACTIVE_COMPARATOR; Interventions: Drug: bactrim | Arm Label: Matched placebo 2 pills po BID x 7 days; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: bactrim; Assigned to Arm(s): bactrim DS (800/160) 2 pills po BID x 7 days | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Matched placebo 2 pills po BID x 7 days
D: Arm Label: Linezolid; Type: ACTIVE_COMPARATOR; Interventions: Drug: Linezolid | Arm Label: CEM-102 Regimen A; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Arm Label: CEM-102 Regimen B; Type: EXPERIMENTAL; Interventions: Drug: CEM-102 | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen A | Intervention Type: DRUG; Name: Linezolid; Assigned to Arm(s): Linezolid | Intervention Type: DRUG; Name: CEM-102; Assigned to Arm(s): CEM-102 Regimen B

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Magnetic Seizure Therapy (MST) for the Treatment of Major Depression
Brief Summary: This two-center, between-subject, randomized, double-masked study (n=20) will provide the first evidence for the antidepressant efficacy of Magnetic Seizure Therapy (MST) and contrast the therapeutic properties and side effects of two forms of MST in patients in a major depressive episode (MDE).


Options:
A: Arm Label: Active Treatment; Type: EXPERIMENTAL; Interventions: Device: MST | Intervention Type: DEVICE; Name: MST; Assigned to Arm(s): Active Treatment
B: Arm Label: Magnetic Seizure therapy (MST); Type: EXPERIMENTAL; Interventions: Device: Magstim Theta | Arm Label: Right Unilateral Electroconvulsive Therapy; Type: ACTIVE_COMPARATOR; Interventions: Device: Thymatron System IV | Intervention Type: DEVICE; Name: Magstim Theta; Assigned to Arm(s): Magnetic Seizure therapy (MST) | Intervention Type: DEVICE; Name: Thymatron System IV; Assigned to Arm(s): Right Unilateral Electroconvulsive Therapy
C: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: Magnetic Seizure Therapy (MST) | Arm Label: Electroconvulsive Therapy (ECT); Type: ACTIVE_COMPARATOR; Interventions: Device: Electroconvulsive Therapy (ECT) | Intervention Type: DEVICE; Name: Magnetic Seizure Therapy (MST); Assigned to Arm(s): Magnetic Seizure Therapy (MST) | Intervention Type: DEVICE; Name: Electroconvulsive Therapy (ECT); Assigned to Arm(s): Electroconvulsive Therapy (ECT)
D: Arm Label: Magnetic Seizure Therapy (MST); Type: EXPERIMENTAL; Interventions: Device: Magnetic Seizure Therapy | Arm Label: Electroconvulsive Therapy (ECT); Type: ACTIVE_COMPARATOR; Interventions: Device: Electroconvulsive Therapy | Intervention Type: DEVICE; Name: Magnetic Seizure Therapy; Assigned to Arm(s): Magnetic Seizure Therapy (MST) | Intervention Type: DEVICE; Name: Electroconvulsive Therapy; Assigned to Arm(s): Electroconvulsive Therapy (ECT)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effects of Exenatide on Postprandial Hyperlipidemia and Inflammation
Brief Summary: The primary goal of this study is to determine the acute effects of exenatide on postprandial hypertriglyceridemia. Secondary goals are to determine whether there are additional improvements in postprandial lipids and lipoproteins and whether (by the reduction of hyperglycemia alone or in combination with declines in hyperlipidemia) exenatide reduces the pro-inflammatory potential of the postprandial period.


Options:
A: Arm Label: Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Normal Saline | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide | Intervention Type: OTHER; Name: Normal Saline; Assigned to Arm(s): Placebo
B: Arm Label: Exenatide first, then Placebo; Type: EXPERIMENTAL; Interventions: Drug: Exenatide, Drug: Placebo | Arm Label: Placebo first, then Exenatide; Type: EXPERIMENTAL; Interventions: Drug: Exenatide, Drug: Placebo | Intervention Type: DRUG; Name: Exenatide; Assigned to Arm(s): Exenatide first, then Placebo, Placebo first, then Exenatide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Exenatide first, then Placebo, Placebo first, then Exenatide
C: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Alogliptin; Type: EXPERIMENTAL; Interventions: Drug: Alogliptin | Intervention Type: DRUG; Name: Alogliptin; Assigned to Arm(s): Alogliptin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: metformin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Metformin | Arm Label: gastric banding; Type: EXPERIMENTAL; Interventions: Device: gastric banding | Intervention Type: DRUG; Name: Metformin; Assigned to Arm(s): metformin | Intervention Type: DEVICE; Name: gastric banding; Assigned to Arm(s): gastric banding

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Affirm: A Multinational Phase 3, Randomized, Double-blind, Placebo-controlled Efficacy And Safety Study Of Oral Mdv3100 In Patients With Progressive Castration-resistant Prostate Cancer Previously Treated With Docetaxel Based Chemotherapy
Brief Summary: This is a phase 3 study to compare the clinical benefit of MDV3100 versus placebo in patients with castration-resistant prostate cancer who have been previously treated with docetaxel-based chemotherapy.


Options:
A: Arm Label: Enzalutamide; Type: EXPERIMENTAL; Interventions: Drug: Enzalutamide | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Enzalutamide; Assigned to Arm(s): Enzalutamide | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Radical prostatectomy; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Radical prostatectomy | Arm Label: Conformal radiation therapy; Type: ACTIVE_COMPARATOR; Interventions: Radiation: Conformal radiation therapy | Arm Label: Active monitoring; Type: ACTIVE_COMPARATOR; Interventions: Other: Active monitoring | Intervention Type: PROCEDURE; Name: Radical prostatectomy; Assigned to Arm(s): Radical prostatectomy | Intervention Type: RADIATION; Name: Conformal radiation therapy; Assigned to Arm(s): Conformal radiation therapy | Intervention Type: OTHER; Name: Active monitoring; Assigned to Arm(s): Active monitoring
C: Arm Label: Apalutamide plus ADT; Type: EXPERIMENTAL; Interventions: Drug: Apalutamide, Drug: Androgen Deprivation Therapy (ADT) | Arm Label: Placebo plus ADT; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: Androgen Deprivation Therapy (ADT) | Intervention Type: DRUG; Name: Apalutamide; Assigned to Arm(s): Apalutamide plus ADT | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus ADT | Intervention Type: DRUG; Name: Androgen Deprivation Therapy (ADT); Assigned to Arm(s): Apalutamide plus ADT, Placebo plus ADT
D: Arm Label: Abiraterone acetate plus prednisone/prednisolone; Type: EXPERIMENTAL; Interventions: Drug: Abiraterone acetate, Drug: Prednisone/prednisolone | Arm Label: Placebo plus prednisone/prednisolone; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Prednisone/prednisolone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo plus prednisone/prednisolone | Intervention Type: DRUG; Name: Abiraterone acetate; Assigned to Arm(s): Abiraterone acetate plus prednisone/prednisolone | Intervention Type: DRUG; Name: Prednisone/prednisolone; Assigned to Arm(s): Abiraterone acetate plus prednisone/prednisolone, Placebo plus prednisone/prednisolone

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Analysis of Calcium Balance in Chronic Kidney Disease
Brief Summary: Subjects with normal kidney function are able to excrete in their urine the calcium and phosphorus absorbed via the gastrointestinal tract and are thereby are able to maintain calcium and phosphorus balance. Patients with chronic kidney disease often have normal blood levels of calcium and phosphorus but no research has been conducted to determine if they are able to excrete their daily intake of these minerals. If they are not able to excrete their daily intake, these minerals could be deposited in soft tissue and blood vessels and contribute to the increased risk of cardiovascular disease seen in patients with chronic kidney disease. This study will determine if subjects with chronic kidney disease are in balance primarily with regard to calcium and at what level of kidney function they are no longer able to maintain balance. Understanding whether patients with chronic kidney disease are in balance will help direct future therapeutic interventions.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Arm Label: Calcium Carbonate (Phosphate Binder); Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: 1500 mg/d elemental calcium as calcium carbonate | Intervention Type: DIETARY_SUPPLEMENT; Name: 1500 mg/d elemental calcium as calcium carbonate; Assigned to Arm(s): Calcium Carbonate (Phosphate Binder) | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Niacinamide | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Niacinamide; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
C: Arm Label: HS219; Type: EXPERIMENTAL; Interventions: Dietary Supplement: HS219 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: HS219; Assigned to Arm(s): HS219 | Intervention Type: DIETARY_SUPPLEMENT; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Subjects with normal kidney function; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: High calcium diet 2000 mg/day, Dietary Supplement: Low calcium diet, 800 mg/day | Arm Label: CKD late Stage 3 and Stage 4; Type: EXPERIMENTAL; Interventions: Dietary Supplement: High calcium diet 2000 mg/day, Dietary Supplement: Low calcium diet, 800 mg/day | Intervention Type: DIETARY_SUPPLEMENT; Name: High calcium diet 2000 mg/day; Assigned to Arm(s): CKD late Stage 3 and Stage 4, Subjects with normal kidney function | Intervention Type: DIETARY_SUPPLEMENT; Name: Low calcium diet, 800 mg/day; Assigned to Arm(s): CKD late Stage 3 and Stage 4, Subjects with normal kidney function

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Intravenous Doses of 3 Dose Levels of CAT-354 in Subjects With Moderate Asthma
Brief Summary: The study includes participants with moderate asthma who were randomly assigned to receive the study medication (CAT-354) or placebo.


Options:
A: Arm Label: CAT-354 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 1mg/kg | Arm Label: CAT-354 5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 5 mg/kg | Arm Label: CAT-354 10mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 10mg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 1mg/kg; Assigned to Arm(s): CAT-354 1 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 5 mg/kg; Assigned to Arm(s): CAT-354 5 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 10mg/kg; Assigned to Arm(s): CAT-354 10mg/kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: N/A; Interventions: N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Arm Label: CAT-354 150 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 150 mg | Arm Label: CAT-354 300 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 300 mg | Arm Label: CAT-354 600 mg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 600 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 150 mg; Assigned to Arm(s): CAT-354 150 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 300 mg; Assigned to Arm(s): CAT-354 300 mg | Intervention Type: BIOLOGICAL; Name: CAT-354 600 mg; Assigned to Arm(s): CAT-354 600 mg
D: Arm Label: CNTO 148 (golimumab); Type: EXPERIMENTAL; Interventions: Drug: CNTO148 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: CNTO148; Assigned to Arm(s): CNTO 148 (golimumab) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double-Blind, Placebo Controlled Study to Assess the Pharmacokinetics, Safety and Tolerability of Multiple Intravenous Doses of 3 Dose Levels of CAT-354 in Subjects With Moderate Asthma
Brief Summary: The study includes participants with moderate asthma who were randomly assigned to receive the study medication (CAT-354) or placebo.


Options:
A: Arm Label: CAT-354 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 1mg/kg | Arm Label: CAT-354 5 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 5 mg/kg | Arm Label: CAT-354 10mg/kg; Type: EXPERIMENTAL; Interventions: Biological: CAT-354 10mg/kg | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: BIOLOGICAL; Name: CAT-354 1mg/kg; Assigned to Arm(s): CAT-354 1 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 5 mg/kg; Assigned to Arm(s): CAT-354 5 mg/kg | Intervention Type: BIOLOGICAL; Name: CAT-354 10mg/kg; Assigned to Arm(s): CAT-354 10mg/kg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: MEMP1972A 150 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 300 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: MEMP1972A 450 mg; Type: EXPERIMENTAL; Interventions: Drug: MEMP1972A | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 300 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 450 mg | Intervention Type: DRUG; Name: MEMP1972A; Assigned to Arm(s): MEMP1972A 150 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
C: Arm Label: OAT + Omalizumab; Type: EXPERIMENTAL; Interventions: Drug: Omalizumab, Other: Optimized asthma therapy | Arm Label: Optimized Asthma Treatment (OAT); Type: ACTIVE_COMPARATOR; Interventions: Other: Optimized asthma therapy | Intervention Type: DRUG; Name: Omalizumab; Assigned to Arm(s): OAT + Omalizumab | Intervention Type: OTHER; Name: Optimized asthma therapy; Assigned to Arm(s): OAT + Omalizumab, Optimized Asthma Treatment (OAT)
D: Arm Label: AMG 317 75 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 75 mg | Arm Label: Placebo Arm; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Arm Label: AMG 317 300 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 300 mg | Arm Label: AMG 317 150 mg; Type: EXPERIMENTAL; Interventions: Biological: AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 75 mg; Assigned to Arm(s): AMG 317 75 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 150 mg; Assigned to Arm(s): AMG 317 150 mg | Intervention Type: BIOLOGICAL; Name: AMG 317 300 mg; Assigned to Arm(s): AMG 317 300 mg | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo Arm

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: DIATOR - Diabetes Intervention With Atorvastatin. A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Investigate the Effect of Atorvastatin on Residual Beta-cell Function and Glycemic Control in Patients With Newly Diagnosed Type 1 Diabetes Mellitus
Brief Summary: Clinical studies have shown that immunomodulators (like Anti-CD3 antibodies) have effects on beta-cell-preservation. The lipid-lowering agent atorvastatin is also a potent immunomodulator. In this study the effects of 80 mg atorvastatin per day on preservation of beta-cell function in recent onset type 1 diabetes were studied, as determined by stimulated C-peptide levels.


Options:
A: Arm Label: atorvastatin matching placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: atorvastatin matching placebo | Arm Label: atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): atorvastatin | Intervention Type: DRUG; Name: atorvastatin matching placebo; Assigned to Arm(s): atorvastatin matching placebo
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Aspirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: Aspirin + Atorvastatin | Intervention Type: DRUG; Name: Aspirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Aspirin + Atorvastatin; Assigned to Arm(s): 4
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Atorvastatin; Type: EXPERIMENTAL; Interventions: Drug: Atorvastatin | Intervention Type: DRUG; Name: Atorvastatin; Assigned to Arm(s): Atorvastatin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: PPAR alpha; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: atorvastatin; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Study To Evaluate The Safety And Efficacy Of IPX066 In Advanced Parkinson's Disease
Brief Summary: This is a study to evaluate the safety and efficacy of IPX066 in advanced Parkinson's disease.


Options:
A: Arm Label: EXPERIMENTAL; Type: EXPERIMENTAL; Interventions: Behavioral: an 8-week blended indoor-outdoor exercise program | Arm Label: CONTROL; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: an 8-week upper limb and hand exercise program | Intervention Type: BEHAVIORAL; Name: an 8-week blended indoor-outdoor exercise program; Assigned to Arm(s): EXPERIMENTAL | Intervention Type: BEHAVIORAL; Name: an 8-week upper limb and hand exercise program; Assigned to Arm(s): CONTROL
B: Arm Label: Experimental group; Type: EXPERIMENTAL; Interventions: Device: Gait Trainer 3 | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Device: Gait Trainer 3 | Intervention Type: DEVICE; Name: Gait Trainer 3; Assigned to Arm(s): Control Group, Experimental group
C: Arm Label: IPX066; Type: EXPERIMENTAL; Interventions: Drug: IPX066, Drug: IR CD-LD | Arm Label: IR CD-LD; Type: ACTIVE_COMPARATOR; Interventions: Drug: IPX066, Drug: IR CD-LD | Intervention Type: DRUG; Name: IPX066; Assigned to Arm(s): IPX066, IR CD-LD | Intervention Type: DRUG; Name: IR CD-LD; Assigned to Arm(s): IPX066, IR CD-LD
D: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Drug: nicotine | Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo comparator | Intervention Type: DRUG; Name: nicotine; Assigned to Arm(s): Nicotine | Intervention Type: OTHER; Name: placebo comparator; Assigned to Arm(s): placebo

Answer: C